Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pediatr.

Sec. Pediatric Endocrinology

Trends in Central Precocious Puberty Incidence in Japan During the COVID-19 Pandemic

Provisionally accepted
Yosuke  KomatsuYosuke Komatsu1,2,3Nobuyuki  KikuchiNobuyuki Kikuchi2,3*Kuniyuki  NishiyamaKuniyuki Nishiyama3,4Koji  OhsugiKoji Ohsugi3,5Kentaro  ShigaKentaro Shiga3,6
  • 1Yokohama City University Medical Center, Children's Medical Center, Yokohama, Japan
  • 2Yokohama Rosai Hospital, Japan Organization of Health and Safety, Yokohama, Japan
  • 3Department of Pediatrics, Yokohama City University, Yokohama, Japan
  • 4Yokohama Medical Center, National Hospital Organization, Yokohama, Japan
  • 5Odawara Municipal Hospital, Odawara, Japan
  • 6Yokohama City University, Children's Medical Center, Yokohama, Japan

The final, formatted version of the article will be published soon.

Background: The incidence of central precocious puberty (CPP) has reportedly increased worldwide during the coronavirus disease 2019 (COVID-19) pandemic; however, multicenter data from Japan remain limited. This study aimed to evaluate temporal changes in the incidence and clinical characteristics of CPP before, during, and after the pandemic. Methods: We conducted a multicenter retrospective observational study across four pediatric endocrinology centers in Kanagawa, Japan. Newly diagnosed CPP cases from 2018 to 2023 were categorized into three periods: pre-pandemic (2018–2019), pandemic (2020–2021), and post-pandemic (2022–2023). Incidence rate ratios (IRRs) were calculated using quasi-Poisson regression, with population size included as an offset. Clinical characteristics—including age at diagnosis, bone age, degree of overweight, and hormone profiles—were compared across periods using the Kruskal– Wallis test. Results: A total of 118 children (94 girls and 24 boys) were diagnosed with CPP during the study period. Among girls, CPP incidence increased significantly during the pandemic compared with the pre-pandemic period (IRR 2.47; 95% confidence interval [CI]: 1.29–5.03). In boys, incidence also increased with a statistically significant IRR; however, the estimate was accompanied by wide confidence intervals owing to the small number of cases. Elevated incidence rates in girls persisted into the post-pandemic period. No significant differences were observed across periods in age at diagnosis, degree of bone age advancement, degree of overweight, or basal and stimulated hormone levels. Nevertheless, the cohort consistently exhibited higher degrees of overweight compared with national reference values. Conclusions: This multicenter study demonstrates a significant increase in CPP incidence among girls during the COVID-19 pandemic in Japan, with sustained elevation in the post-pandemic period. Although clinical characteristics remained largely unchanged, the consistently higher degree of overweight underscores the need to consider lifestyle and environmental factors that may have been exacerbated during the pandemic. Ongoing surveillance and reevaluation of CPP diagnostic criteria may be warranted to address emerging epidemiological trends.

Keywords: central precocious puberty, Childhood Obesity, COVID-19 pandemic, Epidemiology, incidence trends, Pediatric Endocrinology

Received: 17 Dec 2025; Accepted: 16 Feb 2026.

Copyright: © 2026 Komatsu, Kikuchi, Nishiyama, Ohsugi and Shiga. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Nobuyuki Kikuchi

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.